Millennium Management
NKTR icon

Millennium Management’s Nektar Therapeutics NKTR Stock Holding History

Millennium Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,153
Closed -$2.06M – 7291
2021
Q4 		$2.06M Buy
+10,153
New +$2.2M ﹤0.01% 3757
2018
Q3 		– Sell
-3,333
Closed -$2.44M – 4159
2018
Q2 		$2.44M Hold
3,333
– – ﹤0.01% 2265
2018
Q1 		$5.31M Buy
+3,333
New +$4.29M 0.01% 1773
2013
Q4 		– Sell
-8,233
Closed -$1.29M – 3666
2013
Q3 		$1.29M Buy
+8,233
New +$1.52M ﹤0.01% 1946

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management's NKTR Position: Q1 2026 in Review

Millennium Management reduced its Nektar Therapeutics (NKTR) stake by 11% in Q1 2026, selling an estimated $2.84M and leaving 404,277 shares worth $29.1M. The position accounts for 0.01% of the portfolio, ranked #1259.

Millennium Management first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. The position peaked at $114M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Millennium Management held 404,277 shares of Nektar Therapeutics worth $29.1M as of Q1 2026.
  • Millennium Management sold 49,798 Nektar Therapeutics shares in Q1 2026, an estimated $2.84M.
  • Nektar Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1259 holding.
  • Millennium Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • Millennium Management's Nektar Therapeutics position peaked at $114M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.